Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains. The rise in cell ...
In the following Q&A, Shawn McGee, VP of National Accounts at A. Duie Pyle, shares insights on today’s key risks, including ...
Gross-to-net concessions exceeding half of U.S. brand revenue make minor contracting and payment inefficiencies translate into hundreds of millions in leakage or compliance risk. Legacy revenue ...
EPS for ~3-day lanes, polyurethane for higher performance, and vacuum insulation panels for maximum duration—still anchor ...
Pharmaceutical cold chain logistics is entering a phase where data quality and decision speed matter as much as physical ...
Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain ...
Regulatory expectations increasingly demand evidence of in-transit control, emphasizing data integrity, auditability, and ...
Structural disruption pressures are rising, making safety stock and excess capacity insufficient as primary risk buffers across highly regulated, temperature-sensitive networks. Digital-twin ...
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access, ...
Rahul Shah and Mack MacKenzie explain how to unlock the ROI that rules-based systems have left on the table.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results